Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy

NCT01288339 is registered in ClinicalTrials.gov with Grupo Espanol Multidisciplinario del Cancer Digestivo as lead sponsor.

NCT NCT01288339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01288339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy
Lead sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2010
Completion date
February 13, 2015
Enrollment
78 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer